Bolt Biotherapeutics (BOLT) Total Liabilities (2020 - 2026)
Bolt Biotherapeutics (BOLT) posted Total Liabilities of $28.2 million for Q1 2026, down 6.74% sequentially from $30.2 million in Q4 2025, and down 27.78% YoY from $39.1 million in Q1 2025.
Bolt Biotherapeutics (BOLT) Total Liabilities (2020 - 2026) Analysis & Trends
Bolt Biotherapeutics has reported Total Liabilities for 7 years, with the latest figure at $28.2 million in Q1 2026.
- Quarterly Total Liabilities fell 27.78% year-over-year to $28.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.2 million (down 27.78% YoY) and the FY2025 annual result came in at $30.2 million, down 28.73% from the prior year.
- Total Liabilities declined to $28.2 million in Q1 2026 per BOLT's latest filing, from $30.2 million in the prior quarter.
- Over five years, Total Liabilities peaked at $57.1 million in Q3 2022 and troughed at $28.2 million in Q1 2026.
- A 5-year average of $43.2 million and a median of $42.4 million in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Liabilities soared 154.33% in 2022, then decreased 28.73% in 2025.
- Over 5 years, Total Liabilities stood at $56.3 million in 2022, then decreased by 16.44% to $47.0 million in 2023, then retreated by 9.8% to $42.4 million in 2024, then fell by 28.73% to $30.2 million in 2025, then fell by 6.74% to $28.2 million in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $28.2 million, $30.2 million, and $33.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 10.03 Bn |
| 10 | Bolt Biotherapeutics | 6.10 Mn | 6.10 Mn | - | 27.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.70 Mn |
| Mar 31, 2026 | 28.21 Mn |
| Dec 31, 2025 | 30.24 Mn |
| Sep 30, 2025 | 32.95 Mn |
| Jun 30, 2025 | 36.66 Mn |
| Mar 31, 2025 | 39.05 Mn |
| Dec 31, 2024 | 42.43 Mn |
| Sep 30, 2024 | 37.30 Mn |
| Jun 30, 2024 | 38.32 Mn |
| Mar 31, 2024 | 38.73 Mn |
| Dec 31, 2023 | 47.04 Mn |
| Sep 30, 2023 | 47.10 Mn |
| Jun 30, 2023 | 48.56 Mn |
| Mar 31, 2023 | 48.50 Mn |
| Dec 31, 2022 | 56.30 Mn |
| Sep 30, 2022 | 57.06 Mn |
| Jun 30, 2022 | 52.27 Mn |
| Mar 31, 2022 | 54.40 Mn |
| Dec 31, 2021 | 57.60 Mn |
| Sep 30, 2021 | 58.64 Mn |